Pharmaceutical Executive
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Doug Balogh
Advertisement
Articles by Doug Balogh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Teva Enters $900 Million Agreement to Acquire Emalex
4
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
5